secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2024-05-13T23:59:59+00:00
Accession:  0001193125-24-136785
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 3.02, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma to merge with OnKure in reverse merger; OnKure stockholders to own 69.4% of combined company
--------------------------------------------------------------------------------

- OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.
- Concurrent $65M PIPE investment committed from OnKure existing stockholders and new investors.
- OnKure valued at $170M, Reneo at $75M; exchange ratios subject to net cash adjustment (±$1M threshold).
- Post-merger board: 8 members, 6 designated by OnKure and 2 by Reneo; current Reneo CEO and execs to resign.
- Reneo will seek stockholder approval for name change to 'OnKure Therapeutics', reverse stock split, and share issuance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/0001193125-24-136785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-136785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer